Tranexamic Acid Administration in Trauma and Significant Bleeding

Introduction

Tranexamic acid (TXA) is recommended for the treatment of trauma and significant bleeding, with guidelines supported by the American College of Critical Care, American College of Obstetricians and Gynecologists, and other medical societies 1, 2, 3

The standard recommended dosing for intravenous TXA in trauma and significant bleeding is a loading dose of 1g administered over 10 minutes, followed by a maintenance dose of 1g infused over 8 hours, as recommended by the Critical Care guidelines 4, 3
Alternative dosing regimens for TXA in different clinical settings are as follows:

Clinical Setting	Recommended Dose
Trauma	1g IV over 10 minutes, followed by 1g over 8 hours
Cardiac/Major Non-Cardiac Surgery	1g IV over 10 minutes, followed by 1g over 8 hours
Postpartum Hemorrhage	1g IV over 10 minutes, with a second 1g dose if bleeding continues after 30 minutes
Hemoptysis	1g IV every 8 hours, not exceeding 3g daily

5, 6, 7

The American Society of Anesthesiologists recommends a loading dose of 15 mg/kg IV, followed by a maintenance dose of 2 mg/kg/hour infusion for TXA administration 8

Early administration of TXA, within 1 hour of injury, results in a significant reduction in death due to bleeding (RR 0.68) 3
Administration of TXA between 1-3 hours from injury results in a moderate reduction in death due to bleeding (RR 0.79) 3
Maximum benefit is achieved when TXA is given within 1 hour of injury/bleeding onset, and it should not be administered after 3 hours from injury/bleeding onset as it may increase mortality risk 3

TXA is contraindicated in patients with subarachnoid hemorrhage, active intravascular clotting, and hypersensitivity to TXA or its ingredients, with a high strength of evidence from clinical guidelines 5, 6
Use with caution in patients with specific conditions such as massive hematuria or those using oral contraceptives due to increased risks of ureteric obstruction and thrombosis, respectively, with a moderate strength of evidence from clinical studies 7

In patients with renal impairment, TXA dosing should be adjusted based on creatinine levels, as shown in the table below, to ensure safe and effective use, with a moderate strength of evidence from clinical studies 5, 6

Serum Creatinine	TXA IV Dosage
1.36-2.83 mg/dL	10 mg/kg twice daily
2.83-5.66 mg/dL	10 mg/kg daily
>5.66 mg/dL	10 mg/kg every 48 hours or 5 mg/kg every 24 hours

Both TXA and dexamethasone can be administered concurrently, but ideally through separate IV lines, with adequate flushing between medications with normal saline if using the same line 2, 4
Desmopressin may be considered for patients with platelet dysfunction or on antiplatelet therapy, as it stimulates the release of von Willebrand factor from the endothelium, with a dosing recommendation of 0.3 μg/kg 7

Patients should be monitored for potential adverse effects of TXA, including nausea, vomiting, hypotension, and rarely seizures or thrombotic events, as indicated by the FDA and National Institutes of Health 6, 5, 3, 9
Monitor for fibrinolysis if possible using thromboelastometric monitoring, and consider stopping antifibrinolytic therapy once bleeding has been adequately controlled 4

In cancer-related disseminated intravascular coagulation (DIC), TXA should not be routinely used except when therapy-resistant bleeding dominates the clinical picture, as recommended by the International Society on Thrombosis and Haemostasis 10
The use of high-dose IV TXA in gastrointestinal bleeding is not recommended due to increased risk of thrombotic events without significant benefit, according to the Society of Critical Care Medicine 11